Skip to main content
. Author manuscript; available in PMC: 2016 Jul 21.
Published in final edited form as: Genet Med. 2015 Jan 15;17(9):702–712. doi: 10.1038/gim.2014.188

Table 1.

Prevalence of family history

Author, year Data Source N Mean age
(range)		 % Female Family history categoriesf Prevalence (%)
Taylor 201017 Utah Population
Database		 2 327 327 NR (NR) NR 1 FDR with CRC 3.9
1+ FDR 4.1
1+ FDR dx age: <50, <60, ≥ 60 0.27, 0.78, 3.38
2 FDR 0.31
2+ FDR 0.34
1+ SDR dx age: <50, <60, ≥ 60 0.84, 2.51, 10.5
Scheuner 201018 2005 CHIS 33 187 39.3 50%
(weighted)		 EITHER no family history *or* 1 SDR dx age ≥50 with CRC or
endometrial cancer *or* 1 FDR with endometrial cancer		 95.7
EITHER 1 FDR *or* 2 SDRs dx age > 50 *or* 1 SDR dx age <50
with CRC and 1+ SDR dx age >50 with endometrial cancer		 4.2
EITHER 1+ FDR dx age <50 *or* 2+ ADR *or* hereditary
syndrome		 1.1
Kondo 200319 JACC 50 864 57.7 57% 1+ parent with CRC 1.7
Pinsky 200320 PLCO 149 332 NR (55–74) 51% 1 FDR 9.4b
2+ FDR 0.7
Sandhu 200165 EPIC- Norfolk
(UK)		 30 353c


 59.1 55% 1+ FDR with CRC 6.8d
2+ FDR 0.3d
EITHER 2 FDR *or* 1 FDR dx age <45 0.6
1+ FDR dx age <45, 45–64, ≥ 65 0.3, 2.0, 3.8d
Poole 199922 CPS – 1 429 483 51 100% 1+ FDR with CRC 3.7
Nelson 199323 Iowa Women's
Health Study		 40 657 NR (55–69) 100% 1+ mother/daughter with CC 3.1
Fuchs 19942 NHS 87 031 49.1 100% 1+ FDR with CRC 9.4e
Fuchs 19942 HPFS 32 085 51.5 0% 1+ FDR with CRC 10e
a

Only individuals without a personal history of cancer (breast, ovarian, ednometrial, prostate, or CRC) (NOTE are weighted %s)

b

Reported: expected ratio by gender male 0.60 (0.57, 0.62 95% CI) female 0.76 (0.73, 0.79 95% CI).

c

non-cases only (n=28155)

d

Adjusted for sex

e

Values are means directly standardized according to the age distribution of the respective cohort in its entirety.

f

Abbreviations: FDR (first degree relative) SDR (second degree relative) ADR (any degree relative) CRC (colorectal cancer), CHIS (California Health Interview Survey), JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk), PLCO (Prostate, Lung, Colorectal, and Ovarian cancer screening trial), CPS (Cancer Prevention Study), EPIC (European Prospective Investigation into Cancer), NHS (Nurses Health Study), HPFS (Health Professional Followup Study)